GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 13-24 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.

Nielsen VW; Holgersen N; Pedersen NH; Brogaard E; Andersen YMF; Egeberg A; Thyssen JP; Thomsen SF

2026PubMedDirectly related

Are we at risk of increasing sarcopenia? Implications for osteoarthritis and osteoporosis.

Pan F; Cicuttini FM

Jan 1, 2026Best practice & research. Clinical rheumatology

2026PubMedDirectly related

Predictors of treatment response to semaglutide for weight management.

Tzoulis P

Jan 1, 2026Frontiers in endocrinology

2026PubMedDirectly related

Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.

Husereau D; Evans M; Hahn-Pedersen JH; King R; Kettle J; Bray BD; Berger M; Luckevich M; Lübker C; Mattke S

Jan 1, 2026Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

2026PubMedDirectly related

Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study.

Kucuk Yetgin M; Gletsu-Miller N; Chapman RR; Gelber E; Snyder J; Gregg D; Nabhan D

Jan 1, 2026Obesity pillars

2026PubMedDirectly related

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes.

Hoog MM; Vallarino C; Maldonado JM; Grabner M; Teng CC; Terrell K; Richard EL

Jan 1, 2026Journal of managed care & specialty pharmacy

2026PubMedDirectly related

Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists.

Carson L; Eisner M; Launay C; Leech S; Weatherhead S

Jan 1, 2026Skin health and disease

2026PubMedDirectly related

GLP-1 receptor agonists in psoriasis management.

Cutrona M; Talia J; Cices A

Jan 1, 2026Clinics in dermatology

2026PubMedDirectly related

Intramuscular Fat as a Biomarker of Muscle Health: Strengths, Limitations and Open Challenges.

Spence C; Belzunce MA; Di Laura A; Henckel J; Hart AJ

Jan 1, 2026Journal of cachexia, sarcopenia and muscle

2026PubMedDirectly related

GLP-1 receptor agonists and bariatric surgery: complement, not competition: An integrated framework for contemporary obesity management: a narrative review.

Chumakova-Orin M; Juo Y; Fanelli R; Irish W; Pories W; DeMaria EJ

Jan 1, 2026Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

2026PubMedDirectly related

Incretin-Based Therapy in Patients with Malignancy and Obesity or Type 2 Diabetes. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF), and Italian Society of Obesity (SIO) Position Paper.

Faggiano A; Argentiero A; Borghesani G; Haxhi J; Camastra S; Cinieri S; Cortellini A; Del Re M; Gallo M; Natalicchio A; Giuffrida D; Gori S; Gristina V; Monami M; Mordivucci L; Ragni A; Randazzo C; Renzelli V; Sciacca L; Tessitore D; Zatelli MC; Di Maio M; Barazzoni R; Marrano N; Ferone D; Silvestris N; Giorgino F

Jan 1, 2026Obesity reviews : an official journal of the International Association for the Study of Obesity

2026PubMedDirectly related

Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonism.

Copling AN; Dinckol O; Wenger NH; Patel BP; N'Kongolo Lukusa EM; Kutlu MG

Jan 1, 2026bioRxiv : the preprint server for biology